Toll Free: 1-888-928-9744

Liver Cancer - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 1073 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Liver Cancer - Pipeline Review, H1 2016', provides an overview of the Liver Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cancer
- The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
- The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
Introduction 9
Liver Cancer Overview 10
Therapeutics Development 11
Liver Cancer - Therapeutics under Development by Companies 13
Liver Cancer - Therapeutics under Investigation by Universities/Institutes 26
Liver Cancer - Pipeline Products Glance 28
Liver Cancer - Products under Development by Companies 31
Liver Cancer - Products under Investigation by Universities/Institutes 50
Liver Cancer - Companies Involved in Therapeutics Development 53
Liver Cancer - Therapeutics Assessment 223
Drug Profiles 250
Liver Cancer - Dormant Projects 999
Liver Cancer - Discontinued Products 1017
Liver Cancer - Product Development Milestones 1021
Appendix 1039
List of Tables
Number of Products under Development for Liver Cancer, H1 2016 44 Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016 45 Number of Products under Development by Companies, H1 2016 46 Number of Products under Development by Companies, H1 2016 (Contd..1) 47 Number of Products under Development by Companies, H1 2016 (Contd..2) 48 Number of Products under Development by Companies, H1 2016 (Contd..3) 49 Number of Products under Development by Companies, H1 2016 (Contd..4) 50 Number of Products under Development by Companies, H1 2016 (Contd..5) 51 Number of Products under Development by Companies, H1 2016 (Contd..6) 52 Number of Products under Development by Companies, H1 2016 (Contd..7) 53 Number of Products under Development by Companies, H1 2016 (Contd..8) 54 Number of Products under Development by Companies, H1 2016 (Contd..9) 55 Number of Products under Development by Companies, H1 2016 (Contd..10) 56 Number of Products under Development by Companies, H1 2016 (Contd..11) 57 Number of Products under Development by Companies, H1 2016 (Contd..12) 58 Number of Products under Investigation by Universities/Institutes, H1 2016 59 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 60 Comparative Analysis by Late Stage Development, H1 2016 61 Comparative Analysis by Clinical Stage Development, H1 2016 62 Comparative Analysis by Early Stage Development, H1 2016 63 Products under Development by Companies, H1 2016 64 Products under Development by Companies, H1 2016 (Contd..1) 65 Products under Development by Companies, H1 2016 (Contd..2) 66 Products under Development by Companies, H1 2016 (Contd..3) 67 Products under Development by Companies, H1 2016 (Contd..4) 68 Products under Development by Companies, H1 2016 (Contd..5) 69 Products under Development by Companies, H1 2016 (Contd..6) 70 Products under Development by Companies, H1 2016 (Contd..7) 71 Products under Development by Companies, H1 2016 (Contd..8) 72 Products under Development by Companies, H1 2016 (Contd..9) 73 Products under Development by Companies, H1 2016 (Contd..10) 74 Products under Development by Companies, H1 2016 (Contd..11) 75 Products under Development by Companies, H1 2016 (Contd..12) 76 Products under Development by Companies, H1 2016 (Contd..13) 77 Products under Development by Companies, H1 2016 (Contd..14) 78 Products under Development by Companies, H1 2016 (Contd..15) 79 Products under Development by Companies, H1 2016 (Contd..16) 80 Products under Development by Companies, H1 2016 (Contd..17) 81 Products under Development by Companies, H1 2016 (Contd..18) 82 Products under Investigation by Universities/Institutes, H1 2016 83 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 84 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 85 Liver Cancer - Pipeline by 4SC AG, H1 2016 86 Liver Cancer - Pipeline by AB Science SA, H1 2016 87 Liver Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016 88 Liver Cancer - Pipeline by ACROVIS Pharma AG, H1 2016 89 Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 90 Liver Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 91 Liver Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016 92 Liver Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 93 Liver Cancer - Pipeline by Alfact Innovation, H1 2016 94 Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 95 Liver Cancer - Pipeline by American Gene Technologies International Inc., H1 2016 96 Liver Cancer - Pipeline by Amgen Inc., H1 2016 97 Liver Cancer - Pipeline by AndroScience Corporation, H1 2016 98 Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H1 2016 99 Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H1 2016 100 Liver Cancer - Pipeline by ArQule, Inc., H1 2016 101 Liver Cancer - Pipeline by Array BioPharma Inc., H1 2016 102 Liver Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 103 Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 104 Liver Cancer - Pipeline by AstraZeneca Plc, H1 2016 105 Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 106 Liver Cancer - Pipeline by Bayer AG, H1 2016 107 Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 108 Liver Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 109 Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 110 Liver Cancer - Pipeline by BioCancell Ltd, H1 2016 111 Liver Cancer - Pipeline by Biogazelle, H1 2016 112 Liver Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 113 Liver Cancer - Pipeline by Bioneer Corporation, H1 2016 114 Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016 115 Liver Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016 116 Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 117 Liver Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 118 Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016 119 Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016 120 Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016 121 Liver Cancer - Pipeline by Celgene Corporation, H1 2016 122 Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 123 Liver Cancer - Pipeline by Celprogen, Inc., H1 2016 124 Liver Cancer - Pipeline by Celsion Corporation, H1 2016 125 Liver Cancer - Pipeline by China Medical System Holdings Limited, H1 2016 126 Liver Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016 127 Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 128 Liver Cancer - Pipeline by Chroma Therapeutics Limited, H1 2016 129 Liver Cancer - Pipeline by CohBar, Inc., H1 2016 130 Liver Cancer - Pipeline by CytRx Corporation, H1 2016 131 Liver Cancer - Pipeline by CZ BioMed Corp, H1 2016 132 Liver Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 133 Liver Cancer - Pipeline by Delcath Systems, Inc., H1 2016 134 Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 135 Liver Cancer - Pipeline by Digna Biotech, S.L., H1 2016 136 Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 137 Liver Cancer - Pipeline by Eisai Co., Ltd., H1 2016 138 Liver Cancer - Pipeline by Eli Lilly and Company, H1 2016 139 Liver Cancer - Pipeline by Endocyte, Inc., H1 2016 140 Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H1 2016 141 Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 142 Liver Cancer - Pipeline by Exelixis, Inc., H1 2016 143 Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 144 Liver Cancer - Pipeline by Genelux Corporation, H1 2016 145 Liver Cancer - Pipeline by Genoscience Pharma, H1 2016 146 Liver Cancer - Pipeline by Genosco, H1 2016 147 Liver Cancer - Pipeline by GenSpera, Inc., H1 2016 148 Liver Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 149 Liver Cancer - Pipeline by Golden Biotechnology Corp., H1 2016 150 Liver Cancer - Pipeline by Green Cross Cell Corporation, H1 2016 151 Liver Cancer - Pipeline by H3 Biomedicine Inc., H1 2016 152 Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 153 Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016 154 Liver Cancer - Pipeline by HitGen LTD, H1 2016 155 Liver Cancer - Pipeline by Horizon Pharma Plc, H1 2016 156 Liver Cancer - Pipeline by Huperion Sarl, H1 2016 157 Liver Cancer - Pipeline by Immunicum AB, H1 2016 158 Liver Cancer - Pipeline by Immunitor, Inc., H1 2016 159 Liver Cancer - Pipeline by Immunomedics, Inc., H1 2016 160 Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016 161 Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016 162 Liver Cancer - Pipeline by In-Cell-Art S.A.S., H1 2016 163 Liver Cancer - Pipeline by Incanthera Ltd., H1 2016 164 Liver Cancer - Pipeline by Incuron, LLC, H1 2016 165 Liver Cancer - Pipeline by InteRNA Technologies B.V., H1 2016 166 Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016 167 Liver Cancer - Pipeline by Jenrin Discovery, Inc., H1 2016 168 Liver Cancer - Pipeline by Johnson & Johnson, H1 2016 169 Liver Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016 170 Liver Cancer - Pipeline by KAHR medical Ltd., H1 2016 171 Liver Cancer - Pipeline by Karcinolys SAS, H1 2016 172 Liver Cancer - Pipeline by Keystone Nano, Inc., H1 2016 173 Liver Cancer - Pipeline by Kite Pharma, Inc., H1 2016 174 Liver Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016 175 Liver Cancer - Pipeline by Kowa Company, Ltd., H1 2016 176 Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016 177 Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 178 Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 179 Liver Cancer - Pipeline by Lytix Biopharma AS, H1 2016 180 Liver Cancer - Pipeline by MaxCyte, Inc., H1 2016 181 Liver Cancer - Pipeline by MedImmune, LLC, H1 2016 182 Liver Cancer - Pipeline by Medivation, Inc., H1 2016 183 Liver Cancer - Pipeline by Medivir AB, H1 2016 184 Liver Cancer - Pipeline by Merck & Co., Inc., H1 2016 185 Liver Cancer - Pipeline by Merck KGaA, H1 2016 186 Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 187 Liver Cancer - Pipeline by Midatech Pharma Plc, H1 2016 188 Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 189 Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016 190 Liver Cancer - Pipeline by Molecular Partners AG, H1 2016 191 Liver Cancer - Pipeline by MolMed S.p.A., H1 2016 192 Liver Cancer - Pipeline by MultiCell Technologies, Inc., H1 2016 193 Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H1 2016 194 Liver Cancer - Pipeline by NormOxys, Inc., H1 2016 195 Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016 196 Liver Cancer - Pipeline by Novartis AG, H1 2016 197 Liver Cancer - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 198 Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H1 2016 199 Liver Cancer - Pipeline by Omeros Corporation, H1 2016 200 Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 201 Liver Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016 202 Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 203 Liver Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016 204 Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H1 2016 205 Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 206 Liver Cancer - Pipeline by Onxeo SA, H1 2016 207 Liver Cancer - Pipeline by OPKO Health, Inc., H1 2016 208 Liver Cancer - Pipeline by Oribase Pharma, H1 2016 209 Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 210 Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 211 Liver Cancer - Pipeline by Peptinov SAS, H1 2016 212 Liver Cancer - Pipeline by Pfizer Inc., H1 2016 213 Liver Cancer - Pipeline by Pharma Mar, S.A., H1 2016 214 Liver Cancer - Pipeline by PharmAbcine, Inc., H1 2016 215 Liver Cancer - Pipeline by PharmaEssentia Corporation, H1 2016 216 Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H1 2016 217 Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 218 Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2016 219 Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H1 2016 220 Liver Cancer - Pipeline by Provecs Medical GmbH, H1 2016 221 Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 222 Liver Cancer - Pipeline by Quimatryx, S.L., H1 2016 223 Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H1 2016 224 Liver Cancer - Pipeline by RedHill Biopharma Ltd., H1 2016 225 Liver Cancer - Pipeline by Regen BioPharma, Inc., H1 2016 226 Liver Cancer - Pipeline by Regulus Therapeutics Inc., H1 2016 227 Liver Cancer - Pipeline by Rigontec GmbH, H1 2016 228 Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H1 2016 229 Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 230 Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016 231 Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 232 Liver Cancer - Pipeline by Silence Therapeutics Plc, H1 2016 233 Liver Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016 234 Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016 235 Liver Cancer - Pipeline by Synovo GmbH, H1 2016 236 Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 237 Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 238 Liver Cancer - Pipeline by Targetome, H1 2016 239 Liver Cancer - Pipeline by Therapure Biopharma Inc., H1 2016 240 Liver Cancer - Pipeline by Theravectys SA, H1 2016 241 Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016 242 Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016 243 Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 244 Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2016 245 Liver Cancer - Pipeline by Tumorend, LLC, H1 2016 246 Liver Cancer - Pipeline by UbiVac, LLC, H1 2016 247 Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016 248 Liver Cancer - Pipeline by Vaxon Biotech, H1 2016 249 Liver Cancer - Pipeline by Vect-Horus S.A.S., H1 2016 250 Liver Cancer - Pipeline by Verlyx Pharma Inc., H1 2016 251 Liver Cancer - Pipeline by VG Life Sciences, Inc., H1 2016 252 Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H1 2016 253 Liver Cancer - Pipeline by Virttu Biologics Limited, H1 2016 254 Liver Cancer - Pipeline by Vyriad, H1 2016 255 Assessment by Monotherapy Products, H1 2016 256 Assessment by Combination Products, H1 2016 257 Number of Products by Stage and Target, H1 2016 259 Number of Products by Stage and Mechanism of Action, H1 2016 269 Number of Products by Stage and Route of Administration, H1 2016 280 Number of Products by Stage and Molecule Type, H1 2016 282 Liver Cancer - Dormant Projects, H1 2016 1032 Liver Cancer - Dormant Projects (Contd..1), H1 2016 1033 Liver Cancer - Dormant Projects (Contd..2), H1 2016 1034 Liver Cancer - Dormant Projects (Contd..3), H1 2016 1035 Liver Cancer - Dormant Projects (Contd..4), H1 2016 1036 Liver Cancer - Dormant Projects (Contd..5), H1 2016 1037 Liver Cancer - Dormant Projects (Contd..6), H1 2016 1038 Liver Cancer - Dormant Projects (Contd..7), H1 2016 1039 Liver Cancer - Dormant Projects (Contd..8), H1 2016 1040 Liver Cancer - Dormant Projects (Contd..9), H1 2016 1041 Liver Cancer - Dormant Projects (Contd..10), H1 2016 1042 Liver Cancer - Dormant Projects (Contd..11), H1 2016 1043 Liver Cancer - Dormant Projects (Contd..12), H1 2016 1044 Liver Cancer - Dormant Projects (Contd..13), H1 2016 1045 Liver Cancer - Dormant Projects (Contd..14), H1 2016 1046 Liver Cancer - Dormant Projects (Contd..15), H1 2016 1047 Liver Cancer - Dormant Projects (Contd..16), H1 2016 1048 Liver Cancer - Dormant Projects (Contd..17), H1 2016 1049 Liver Cancer - Discontinued Products, H1 2016 1050 Liver Cancer - Discontinued Products (Contd..1), H1 2016 1051 Liver Cancer - Discontinued Products (Contd..2), H1 2016 1052 Liver Cancer - Discontinued Products (Contd..3), H1 2016 1053


List of Figures
Number of Products under Development for Liver Cancer, H1 2016 44 Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016 45 Number of Products under Development by Companies, H1 2016 46 Number of Products under Investigation by Universities/Institutes, H1 2016 59 Comparative Analysis by Clinical Stage Development, H1 2016 62 Comparative Analysis by Early Stage Products, H1 2016 63 Assessment by Monotherapy Products, H1 2016 256 Assessment by Combination Products, H1 2016 257 Number of Products by Top 10 Targets, H1 2016 258 Number of Products by Stage and Top 10 Targets, H1 2016 258 Number of Products by Top 10 Mechanism of Actions, H1 2016 268 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 268 Number of Products by Top 10 Routes of Administration, H1 2016 279 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 279 Number of Products by Top 10 Molecule Types, H1 2016 281 Number of Products by Stage and Top 10 Molecule Types, H1 2016 281

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify